Therapeutic potential of APP antisense oligonucleotides for Alzheimer’s disease and down syndrome-related Alzheimer’s disease
Open Access
- 29 July 2024
- journal article
- research article
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 19 (1) , 1-3
Abstract
No abstract availableKeywords
Funding Information
- Alzheimer’s Research UK (Alzheimer’s Research UK)
- Lister Institute of Preventive Medicine (Lister Institute of Preventive Medicine)
This publication has 10 references indexed in Scilit:
- APP antisense oligonucleotides reduce amyloid-β aggregation and rescue endolysosomal dysfunction in Alzheimer’s diseaseBrain, 2024
- Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disordersCommunications Medicine, 2024
- Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trialNature Medicine, 2023
- The amyloid hypothesis in Alzheimer disease: new insights from new therapeuticsNature Reviews Drug Discovery, 2022
- Genome-wide association study identifies new risk loci for Alzheimer diseaseNature Reviews Neurology, 2021
- Endolysosome and autophagy dysfunction in Alzheimer diseaseAutophagy, 2021
- Synergy between amyloid-β and tau in Alzheimer’s diseaseNature Neuroscience, 2020
- Targeting Amyloid-β Precursor Protein, APP, Splicing with Antisense Oligonucleotides Reduces Toxic Amyloid-β ProductionMolecular Therapy, 2018
- The Cellular Phase of Alzheimer’s DiseaseCell, 2016
- Central and Peripheral Administration of Antisense Oligonucleotide Targeting Amyloid-β Protein Precursor Improves Learning and Memory and Reduces Neuroinflammatory Cytokines in Tg2576 (AβPPswe) MiceJournal of Alzheimer’s Disease, 2014